Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) is evaluating the monetization of approximately $20 million in non-core assets to enhance liquidity and support growth. Identified assets include about $15 million of independently valued real estate plus digital assets, marketable securities, and other liquid holdings, all described as not essential to core healthcare operations.
Real estate options under review include sale, sale-leaseback, or borrowing. The company indicates real estate value alone exceeds its current market capitalization and notes potential uses of proceeds such as funding a meaningful acquisition or achieving a net debt-free position.
Cosmos Health (NASDAQ:COSM) reported a stronger balance sheet and reaffirmed its growth outlook. Q1 2026 liabilities fell by $4.5 million (9.6%) quarter-over-quarter, while stockholders' equity rose 7.6% and the liabilities-to-assets ratio improved to 68.2%.
About 4.9 million Series B warrants expired unexercised, eliminating roughly 38% of warrant overhang with no dilution. The company is in discussions with the European Investment Bank for up to €25 million in R&D financing, holds real estate valued at about $15 million exceeding its market cap, and has a $300 million digital asset financing facility. FY2025 revenue reached a record $65.3 million, up 20% year-over-year, with Q1 2026 revenue of $17.9 million up 31%. Guidance through 2029 targets revenue of $200.6 million, gross margin of 35.5%, adjusted EBITDA of $44.2 million, cash of $62.9 million, and stockholders' equity of $92.3 million, with cash expected to exceed total debt by 2027. The company notes no known business reason for the recent share price decline.
Cosmos Health (NASDAQ:COSM) issued 2026–2029 guidance targeting strong growth and margin expansion. Revenue is projected to rise from $65.3M in 2025 to $200.6M in 2029 (32% CAGR), with gross profit increasing to $71.2M and gross margin to 35.5%.
Net income is projected to swing from a $19.1M loss in 2025 to $31.0M profit in 2029, with profitability expected in 2027. Adjusted EBITDA is guided to $44.2M by 2029, operating cash flow to $24.0M, cash to $62.9M, and stockholders’ equity to $92.3M, with all convertible notes anticipated to be repaid.
Cosmos Health (NASDAQ:COSM) announced that 4,874,126 Series B warrants, representing approximately 38% of its total outstanding warrants, expired unexercised at 5:00 p.m. New York City time on May 19, 2026.
The warrants had a $0.95 exercise price. Their expiration issues no new shares, causes no dilution, reduces warrant overhang, and simplifies the capital structure.
Cosmos Health (NASDAQ:COSM) reported record Q1 2026 revenue of $17.93M, up 30.7% from $13.71M in Q1 2025, with adjusted revenue of $18.40M. Gross profit was $1.38M and adjusted gross profit $1.85M. Net loss widened to $2.81M, while adjusted EBITDA was near breakeven at -$0.23M.
Total liabilities fell 9.6% to $42.54M, stockholders' equity rose 7.6% to $19.83M, and liquid assets totaled $4.3M, including $2.2M cash. Management noted record momentum continuing into Q2 2026 and highlighted active U.S. nutraceuticals expansion.
Cosmos Health (NASDAQ:COSM), via subsidiary Cana Laboratories, entered an advisory agreement with the European Investment Bank (EIB) to advance a potential EIB-backed R&D financing program.
The EIB Venture Debt scheme could fund up to €25M, or 50% of Cosmos Health's planned €50M R&D program, subject to milestones and no assurance of completion.
Potential funding is aimed at accelerating the Company's AI-powered R&D pipeline across weight management, oncology, multiple sclerosis, gliomas, hematologic malignancies, and allergic inflammation.
Cosmos Health (NASDAQ:COSM) has requested withdrawal of its Registration Statement on Form S-1 (File No. 333-283910) with the SEC. The S-1, originally filed December 18, 2024 and last amended June 3, 2025, covered a planned public offering the company no longer intends to pursue at this time.
The Registration Statement was never declared effective, and no securities were sold in connection with the proposed offering. The company notes this announcement is not an offer or solicitation to buy or sell securities.
Cosmos Health (NASDAQ:COSM) projects its new nutraceutical Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months, based on current commercialization plans and internal assumptions.
Fort18™, targeting men's sexual stamina and endurance, is expected to launch in June 2026 via a staged rollout starting with e-commerce.
Cosmos Health (NASDAQ:COSM) announced the U.S. launch of Fort18™, a men's sexual stamina supplement joining its 18 Series on May 6, 2026. Fort18™ uses a proprietary five-ingredient botanical blend standardized to ≥20% saponins and 1.5% flavonoids and is dosed at 500mg twice daily.
Published clinical research (randomized, double-blind, placebo-controlled; n=60) reported a 5.1-fold improvement in endurance versus placebo over eight weeks, with onset by Week 4. IP for the blend's standardization fingerprint is held by the ingredient supplier.
Cosmos Health (NASDAQ:COSM) projects Cur18™ will generate over $2.5 million in incremental annual U.S. revenue within 12–18 months based on its current commercialization strategy and internal assumptions. Cur18™ is a curcumin-based nutraceutical in the company’s 18 Series, planned initially for DTC e-commerce with potential retail expansion.
The projection depends on execution of pricing, sales volumes, and distribution expansion.